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Background: Malignant pleural effusion (MPE) is a common complication of advanced lung cancer. Research has
shown that secreted phosphoprotein-1 (SPP1) is essential in MPE associated with lung cancer. This retrospective
study was performed to evaluate the prognostic significance of SPP1 in the MPE of patients with non-small cell
lung cancer (NSCLC).
Methods: MPE specimens were obtained from 85 NSCLC patients (study group), and pleural effusion specimens
were obtained from 24 patients with benign lung disease (control group). Specimens were tested for SPP1
using enzyme-linked immunosorbent assay (ELISA). Based on the cutoff value of receiver operating characteristic
(ROC) curve analysis, the study patients were divided into a high-SPP1-expression subgroup and a low-expression
subgroup. The primary and secondary endpoints of this study were progression-free survival (PFS) and overall
survival (OS).
Results: The SPP1 levels of the study group were significantly higher compared to those of the controls
(Mann–Whitney U test, P = 0.017). The number of extrapulmonary metastases was significantly higher in the
high-SPP1-expressing patients than in the low-expressing patients (P = 0.03). Kaplan-Meier survival analysis
showed that SPP1 levels were negatively associated with OS and PFS in both subgroups of study patients
(P = 0.026; P = 0.039, respectively). Cox regression analysis showed that SPP1 was an independent prognostic
factor in patients with NSCLC (HR = 1.832, 95% confidence interval: 1.003–3.345; P = 0.049).
Conclusion: SPP1 in pleural effusion can be used for the auxiliary diagnosis of MPE and used to determine the
prognosis of patients with NSCLC.
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PrognosisBackground
The incidence and mortality of lung cancer remain ob-
stinately high with the environment deterioration and
the population aging [1,2]. Malignant pleural effusion
(MPE), a common complication of advanced lung can-
cer, severely impedes respiration and circulation, affect-
ing patients’ life quality [3] with greatly shortened
survival period [4]. Currently, diagnosis accuracy and* Correspondence: yong_song6310@yahoo.com
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reproduction in any medium, provided the ortreatment efficacy for MPE are still to be improved [5],
and individual tumor markers such as carcinoembryonic
antigen (CEA) and cytokeratin 19 fragments (CYFRA
21–1) in making diagnosis is also unsatisfactory [6,7].
Therefore, further study on MPE is necessary for reliable
diagnostic methods.
Secreted phosphoprotein 1 (SPP1), also known as
osteopontin, is a secreted arginine-glycine-aspartic acid
(RGD)-containing phosphorylated glycoprotein with a
molecular weight of about 325,000 [8]. It was first iso-
lated as an extracellular matrix (ECM) protein from
bone matrix [9]. The human SPP1 gene locates on
chromosome 4 (4q13) with 7 exons and 6 introns [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 The characteristic between study group and
case–control group







64 (36–86) 61 (23–86)
Disease Non-small cell lung cancer Benign lung disease
Adenocarcinoma 67 Pulmonary
tuberculosis 18




Unkown-subtype* 4 AECOPD^ 2
*Unknown-subtype: malignant cells were found in the exfoliative cytology of
pleural fluid, and the pathological features resembled non-small cell lung
cancer but could not be definitively identified its subtype. ^AECOPD: acute
exacerbation of chronic obstructive pulmonary disease.
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osteoclasts, macrophages, epithelial cells, endothelial
cells [11,12]. In addition, tumor cells can also secrete
soluble SPP1, which is different from the matrix
protein [13].
The expression of SPP1 is strongly associated with
tumorigenesis and tumor metastasis. It has been noted
that the expression of SPP1 is high in numerous tumors,
including lung cancer [14,15]. Ongoing research has dis-
covered that SPP1 in MPE due to lung cancer has nu-
merous effects: it progresses the tumor both in its
growing and metastasis, and prolongs the survival of
cancer cells [16]. Moreover, SPP1 increases vascular per-
meability. Cui et al. found that SPP1 could increase
pleural vascular permeability by inducing vascular endo-
thelial growth factor (VEGF) expression [17]. Additional
studies have confirmed that SPP1 has a non-VEGF-
dependent effect on vascular permeability as well. Also,
SPP1 promotes intrapleural cancer dissemination [18].
The invasion of ECM by tumor cells may lead to condi-
tions favorable for metastasis [19]. In an in vitro study,
Hu et al. found that SPP1 promotes invasion of ECM by
NSCLC cells, and its effect may be blocked by SPP1
antibodies [20]. Therefore, SPP1 is essential in the for-
mation and development of MPE.
To the best of our knowledge, however, there have
not been any studies on the relationship between SPP1
in MPE and the diagnosis and prognosis of lung can-
cer. So this study is performed to investigate whether
the expression of SPP1 in MPE associated with




85 NSCLC patients, 43 men and 42 women, aged 36–86
years, with a mean age of 64, treated at Jinling Hospital
(Nanjing, Jiangsu Province, China) from January 1, 2010
to December 31, 2012, were retrospectively enrolled for
the trials. NSCLC was confirmed by either exfoliative cy-
tology of pleural fluid or pleural biopsy. All pleural fluids
were confirmed MPE by exfoliative cytology of pleural
fluid, 7 and some patients received pleural biopsy for
their histopathology. The malignancies included 13
squamous cell carcinomas, 67 adenocarcinomas, 1 ade-
nosquamous carcinoma, and 4 unknown cancers (malig-
nant cells were noted in the exfoliative cytology of
pleural fluid, and the pathological features resembled
NSCLC but the subtypes could not be confirmed)
(Table 1). All the lung cancer patients received at least
2 cycles of platinum-based, standard first-line chemo-
therapy or targeted therapy. All study patients had stage
IV cancer according to the 7th edition of the AJCC/
UICC TNM system. The treatment efficacy was accessedfollowing the Response Evaluation Criteria in Solid Tu-
mors (RECIST) 1.1.
24 pathologically confirmed benign lung disease pa-
tients, 14 men and 10 women, aged 23–86 years, with a
mean age of 61, were taken as controls. There were 18
patients with tuberculous pleurisy, 2 with acute exacer-
bation of chronic obstructive pulmonary disease, 2 with
lung infections, and 2 with pulmonary aspergillosis
(Table 1).
Pleural fluid specimens
Both malignant and nonmalignant pleural effusion speci-
mens were collected from the study patients and con-
trols respectively. Follow-up of the study patients began
from the date of specimen collection. The follow-up
ended until patient death or the follow-up period finish
on January 31, 2013. Five patients were lost to follow-up.
The progression-free survival for MPE was defined as
from the time diagnosed with pleural effusion to signifi-
cant progression. Significant progression are confirmed
in those with target lesions in solid tumors considered
as progression according to RECIST 1.1 and the malig-
nant pleural fluid volume is rising rapidly compare with
its baseline during therapy. All patients signed informed
consent and the study was approved by Ethics Commit-
tee of Jinling Hospital.
Fresh pleural fluid specimens were collected from pa-
tients and kept in 10 ml centrifugal tubes without addi-
tive solution and centrifuged at 1000 × g for 15 minutes
within 30 minutes after collection, and then stored in
Eppendorf tubes in a −20°C freezer until analysis.
The specimens were placed at room temperature for
5 minutes for thawing. There is no dilution criterion
Zhang et al. BMC Cancer 2014, 14:280 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/280about samples of pleural fluid according to the direc-
tions of ELISA kit (DOST00, R&D System Company,
Minneapolis, MN, USA). We randomly take 1 piece of
sample from both study group and case–control group,
then took the OPN Standard (200 ng/ml) from the
ELISA kit using the Calibrator Diluent RD5-24 (DOST00,
R&D System Company, Minneapolis, MN, USA) to pro-
duce 1:5, 1:10, 1:50 and 1:100 diluted samples to run a
mini pilot experiment. With the Calibrator Diluent RD5-
24 served as the zero standard (0 ng/ml), the result
showed that samples from either study group or case–
control group which diluted in 100-fold were well con-
sistent with the OPN Standard performed in OD values.
Based on the results of this pilot experiment, all the
specimens were diluted 100-fold with Calibrator Diluent
RD5-24 before low-speed centrifugation (100 × g) for
3 min. The specimens were assayed using the Human
Osteopontin (OPN) Immunoassay Quantikine ELISA kit
(DOST00, R&D System Company, Minneapolis, MN,
USA) following the manufacturer’s instructions. The re-
sults were read on a microplate reader (ELx808, Bio-Tek
Instruments,Winooski, VT, USA) at 450 nm, with a cor-
rection wavelength at 540 nm). The corresponding OD
values were obtained.
Statistical analysis
A point-to-point calculation was performed to establish
the standard curve (r = 0.99992). The SPP1 concentra-
tions were calculated from the absorbances. The SPP1
concentrations of the study patients were compared to
those of the control patients using the Mann–Whitney
U test and the results were shown as median andFigure 1 The box plot of concentrations of SSP1 of malignant pleuralquartile interval. A cut-off value, selected by receiver op-
erating characteristic curve (ROC) analysis, was used to
divide the patients from the study group into 2
subgroups: low-SPP1-expressing patients with SPP1 con-
centrations lower than the cut-off value; and high-SPP1-
expressing patients with SPP1 concentrations not lower
than the cut-off value. The differences in gender, age,
smoking history, tumor pathology, regional lymph node
stage, and number of extrapulmonary metastases of the
SPP1 high- and low-expressing patients were analyzed
using chi-square test. The PFS and OS of the patients
were compared using Kaplan-Meier survival analysis.
Prognostic factors were analyzed using Cox regression




SPP1 expression was detected in all 109 pleural effu-
sion specimens (Figure 1). The SPP1 concentration in
study group and case–control group were tested by
Kolmogorov-Smirnov test separately to examine their
distribution. The SPP1 levels in case–control group were
normally distributed (P = 0.860) while in study group were
not normally distributed (P = 0.004). The SPP1 concentra-
tion was significantly higher in the study patients (median =
925.55 ng/ml and quartile interval = 1651.06 ng/ml) than
in the control patients (median = 544.89 ng/ml and quar-
tile interval = 574.11 ng/ml) (Mann–Whitney U test P =
0.017). The median concentration of SPP1 was about 1.7-
fold higher in the study patients than in the control
patients.effusion and nonmalignant pleural effusion.
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The ROC curve was made according to the SPP1 levels
of both patients groups (Figure 2). The cut-off value was
1247.90 ng/ml (sensitivity 40.3%; specificity 95.8%; area
under the curve (AUC) 0.660; 95% confidence interval
(CI): 0.550-0.770), indicating that the SPP1 concentra-
tion in pleural effusion may have a role in the auxiliary
diagnosis of MPE. High expression of SPP1 implicates
high diagnostic specificity. Patient with high SPP1 is
strongly suggestive of MPE.
SPP1 levels in MPE and clinical features
High-SPP1-expression was noted in 34 patients, 14 men
and 20 women, 2 with squamous cell carcinoma, 28 with
adenocarcinoma, 1 with adenosquamous carcinoma, and
3 with unknown cancers. Low-SPP1-expression was
noted in 51 patients, 29 men and 22 women, 11 with
squamous cell carcinoma, 39 with adenocarcinoma and
1 with unknown cancer. The Pearson chi-square test
showed that gender, age (≤60 years old vs > 60 years
old), smoking history (<20 pack year vs ≥ 20 pack year),
histological type of lung cancer (adenocarcinoma vs
squamous cell carcinoma), and regional lymph node
stage (≤N1 vs > N1) were not significantly differentFigure 2 ROC curve of the SPP1 values in pleural effusion. SPP1 in PF
with NSCLC. The cut-off value was calculated to be 1247.90 ng/ml (sensitiv
confidence interval (CI): 0.550-0 .770). Based on cut-off value the positive pbetween the low- and high-expressing patients (P =
0.156, P = 0.854, P = 0.318, P = 0.072, and P = 0.164, re-
spectively). The high-SPP1-expressing patients had a
significantly greater number of extrapulmonary metasta-
ses than the low-expressing patients (P = 0.03), suggest-
ing that SPP1 levels in the pleural effusion of NSCLC
patients were positively correlated with the number of
extrapulmonary metastases (Table 2).
SPP1 in MPE and the prognosis of patients with NSCLC
The low-SPP1-expressing patients has significantly lon-
ger median PFS (119 days) than that of high-expressing
patients (84 days) (P = 0.039) (Figure 3), and so it is with
the median OS (468 days) than for the high-expressing
patients (301 days) (P = 0.026) (Figure 4). The results
suggest that SPP1 levels in the MPE of patients with
NSCLC were negatively correlated with prognosis.
Multivariate survival analysis using the Cox regression
model, which evaluated 7 factors, including gender, age
(≤60 years vs > 60 years), smoking history (<20 pack year
vs ≥ 20 pack year), histological type of lung cancer
(adenocarcinoma vs squamous cell carcinoma vs adenos-
quamous carcinoma), regional lymph node stage (≤N1
vs > N1), number of extrapulmonary metastases, andfrom all 109 patients are 24 suffered from benign lung disease and 85
ity, 40.3%; specificity, 95.8%; area under the curve (AUC), 0.660; 95%
redictive value is 97.1%; negative predictive value is 31.1%.
Table 2 The relationship between SPP1 expression level
and different clinical and pathological features
Characteristics Total Low-SPP1* High-SPP1 P
NO. % NO. % NO. %
Gender 0.156
Men 43 51 29 56 14 41.2
Women 42 49 22 44 20 58.8
Age 0.854
≤60 31 36.5 19 37.3 12 35.3
>60 54 63.5 32 62.7 22 64.7
Smoking History 0.318
<20 52 61.2 29 56.9 23 67.6
≥20 33 38.8 22 43.1 11 32.4
Histology 0.072
Adenocarcinoma 67 78.8 39 76.5 28 82.4
Squamous 13 15.3 11 21.6 2 5.9
Adenosquamous 1 1.2 0 0 1 2.9
Unknown 4 4.7 1 1.9 3 8.8
Lymphatic Metastasis 0.164
≤N1 14 16.5 6 11.8 8 23.5
>N1 70 82.4 44 86.3 26 76.5
Unknown 1 1.1 1 1.9 0 0
Metastasis organ 0.03
0 27 34.4 21 42.4 6 21.6
≥1 53 57.3 28 50.8 25 67.6
Unknown 5 8.3 2 6.8 3 10.8
*SPP1: secreted phosphoprotein-1.
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expressing), showed that SPP1 was an independent prog-
nostic factor in patients with MPE associated with
NSCLC (hazard ratio = 1.832, 95% CI = 1.003-3.345; P =
0.049) (Table 3).
Discussion
In this study, the concentration of SPP1 in pleural effu-
sion samples from 109 patients was determined by
ELISA. SPP1 concentrations were significantly higher in
the MPE patients than those in the control patients.
Based on the cutoff value, the higher the SPP1 levels in
pleural effusion specimens were, the lower the false diag-
nosis rate of MPE would be. In addition, SPP1 levels in
MPE specimens were positively correlated with the
number of extrapulmonary metastases, and the progno-
sis of patients was significantly better in the low-SPP1-
expressing patients than in the high-expressing patients.
SPP1 in MPE was an independent prognostic factor of
NSCLC-induced MPE, indicating that SPP1 in pleural
effusion can be used for the auxiliary diagnosis ofNSCLC-induced MPE, and it may be a prognostic indi-
cator for patient survival and risk of extrapulmonary
metastases.
Few investigators have studied the diagnostic and
prognostic value of SPP1 in MPE associated with lung
cancer, but data on SPP1 on cancer progression is in-
creasing in recent years. Neal et al. found that patients
with colon cancer, breast cancer, prostate cancer, and
lung cancer had increased SPP1 levels in serum com-
pared with healthy controls; it was almost 2 times higher
in patients with lung cancers. Schneider et al. deter-
mined the expression levels of SPP1 and osteonectin
(ON) in lung cancer tissues using quantitative reverse-
transcription polymerase chain reaction and found that
it was the increased expression of SPP1 rather than ON
was associated with poor prognosis [21]. By testing SPP1
levels in stage I-IIIA NSCLC tissues using immunohisto-
chemistry, and follow-ups for patient outcomes, Italian
investigators found that Stage I patients with high ex-
pression of SPP1 had poorer prognosis than those with
low expression of SPP1 [22]. Mack et al. assessed
plasma SPP1 levels of 56 patients with advanced
NSCLC who received paclitaxel + carboplatin chemo-
therapy in the clinical SWOG Study S0003 and con-
tinuously monitored plasma SPP1 levels and the
treatment response of patients during cycles of chemo-
therapy. They found that plasma SPP1 levels were sig-
nificantly associated with treatment response, PFS and
OS. Patients with low plasma SPP1 levels had better
OS and PFS than those with high levels [23]. Our re-
sults are in consistent with these previous studies;
however, those studies did not analyze the association
between SPP1 level and different clinical features, they
and investigated samples of tumor tissue or blood in-
stead of pleural effusion.
Some of the findings on SPP1 concentrations in MPE
have been studied. Morsi et al. determined the SPP1
concentrations of serum and pleural effusion from 80
patients (20 with transudative effusion; 30 with MPE, in-
cluding 14 patients with NSCLC; 30 with tuberculous ef-
fusion) using ELISA. Their findings suggested that there
was minimal difference between the serum SPP1 levels
and effusion/serum SPP1 ratios of the patients with
MPE and those with tuberculous effusion [24]. However,
Moschos et al. measured serum and pleural effusion
levels of SPP1 from 109 patients (42 with MPE, includ-
ing 19 patients with NSCLC; and 67 with benign dis-
eases) using ELISA, and found that patients with MPE
had higher pleural effusion levels and lower serum levels
of SPP1 than those with benign disease [25]. Our study
showed that SPP1 levels in MPE were significantly
higher in the study group than those of the controls. We
hypothesize that the findings of Morsi et al. might be at-
tributed to the heterogeneity in malignant effusion as
Figure 3 Kaplan-Meier survival analysis of 85 patients with MPE due to NSCLC. The median progression-free survival (PFS) was significantly
longer for the low-SPP1-expressing patients (119 days) than for the high-expressing patients (84 days) (P = 0.039). CUM survival: cumulative survival;
Survival Functions: the function of Kaplan-Meier survival analysis.
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and metastases of the sort of group was smaller than the
remaining cases. The rest 12 cases are not lung cancer
patients, which could lead to larger secretory differenti-
ation and less patients with MPE.Figure 4 Kaplan-Meier survival analysis of 85 patients with MPE due
longer for the low-expressing patients (468 days) than for the high-express
Survival Functions: the function of Kaplan-Meier survival analysis.Although novel technologies are continually being in-
troduced, pleural fluid analysis is still inadequate for the
diagnosis of MPE. The diagnostic characteristics of sin-
gle tumor marker in pleural effusion has been reported
as follows: CEA (sensitivity 45.9%; specificity 97.0%),to NSCLC. The median overall survival (OS) was also significantly
ing patients (301 days) (P = 0.026). CUM survival: cumulative survival;
Table 3 Multivariate Cox regression analysis of
prognostic factors in NSCLC
Variable P HR* 95.0% CI for HR
Lower Upper
Gender 0.775 1.098 0.579 2.082
Age 0.951 1.019 0.555 1.873
Smoking History 0.273 0.681 0.392 1.159
Histology 0.387 1.499 0.599 3.749
Lymphatic Metastasis 0.388 1.405 0.649 3.042
Metastasis Organ 0.734 0.894 0.469 1.706
SPP1^ Groups 0.049 1.832 1.003 3.345
*HR: hazard ratio; ^SPP1: secreted phosphoprotein-1.
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tivity 51%; specificity 96%), CA19-9 (sensitivity 25%; spe-
cificity 96%) and CYFRA21-1 (sensitivity 55%; specificity
91%) [6,7]. In this study, we have shown that SPP1 in
pleural effusion has diagnostic characteristics for MPE
similar to those of CEA in pleural fluid.
In addition, our results suggested that the level of
SPP1 in MPE was an independent prognostic factor for
NSCLC. Both PFS and OS were significantly better in
the low-SPP1-expressing patients than in the high-
expressing patients. Chi-square analysis showed that
SPP1 levels were positively correlated with the number
of extrapulmonary metastases, indicating that patients
with high levels of SPP1 expression had higher risk of
extrapulmonary metastasis. This finding is consistent
with the results from a previous study showing that
SPP1 can promote tumor growth and metastasis [11].
As previously mentioned, high SPP1 concentrations
can inhibit apoptosis of pleural tumor cells and pro-
mote intrapleural tumor dissemination. We also con-
jecture that high levels of SPP1 may prompts tumor
cells invasion of the ECM into parietal pleura, proceed-
ing to intravasation of tumor cells into the blood
stream and subsequent extravasation assisted with uro-
kinase plasminogen activator (uPA) and matrix metal-
loproteases (MMPs), leading to migration of neoplastic
cells to form metastasis at secondary sites. In con-
clusion, high concentrations of SPP1 in pleural fluid
(especially ≥ 1247.9 ng/ml) are more dangerous and
aggressive.
In this study, we evaluated the value of SPP1 as an in-
dicator for the auxiliary diagnosis of MPE and for the
prognosis of patients with NSCLC. The cutoff value de-
termined in this study is specific but not sensitive
enough, which might have resulted in false-negative re-
sults in patients with low SPP1 levels. The reasons for
low sensitivity may be the following: a) Interindividual
differences may be enhanced when the sample amountis small; b) SPP1 is also related to the formation of lung
granulomas because of its role in cellular immunity [26],
as research has shown that circulating SPP1 levels in pa-
tients with pulmonary tuberculosis were significantly
higher than in healthy controls, while the levels might
reflect the activity of tuberculosis [27]; and c) SPP1
levels in exudative pleural effusion (e.g., tuberculous
pleural effusion) were significantly higher than those in
transudative hydrothorax [24,25]. There is a high preva-
lence of tuberculous pleurisy in China, and patients with
tuberculous pleurisy in our study accounted for as many
as 75% of together with the control patients, while pa-
tients with transudative hydrothorax only accounted for
8.3%. The control group was composed of patients
whose disease were not well-controlled, either inflamma-
tion originated from pulmonary or granulomatous
diseases could be disseminated to pleural space in non-
malignant patients and then followed the pleural fluid
from the histopathological lesion. This may have
accounted for a high level of SPP1 in the control pa-
tients, and the value for the controls overlapped the
value for the study patients with low expression levels of
SPP1. This would lead to reduced sensitivity of the cut-
off value.
Our study has inevitable limitations because of various
cancers that induce MPE are dramatically different in
cellular morphology and biological behaviors. Therefore,
further studies with larger sample sizes and optimized
pathological types of cancer are needed to verify our
findings. We could not measure the corresponding
serum samples because the serum samples were not ad-
equate to match all of pleural fluid in the study. This
needs valid research in future studies.Conclusion
In summary, our study suggests that quantitative deter-
mination of SPP1 concentrations in pleural effusions
may provide an auxiliary diagnostic modality for differ-
entiating between benign and malignant pleural effusion.
An increased level (≥1247.90 ng/ml) in MPE may be an
indicator of poor prognosis and risky for distant metas-
tasis. This approach is simple and feasible. Further study
is needed because the pathogenesis of MPE is compli-
cated and the pathological mechanisms of association
between SPP1 and MPE remain unclear.Abbreviations
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